DKSH Holding has announced the acquisition of Swiss Refarmed Group, strengthening its capabilities in the life sciences. Through the acquisition, DKSH Business Unit Performance Materials, the leading global distributor of innovative pharmaceutical ingredients synthesis and formulation with vast and constantly growing global geographic reach, obtains a uniquely positioned business which provides value-added products and services […]
Eversheds Sutherland has advised the founder and long-time chairman Hans Jäggi on his succession and the sale of ADMEDICS, Advanced Medical Solutions, to the managing director, Rudolf Meier. ADMEDICS was founded in 2007 by Hans
Change of hands in Engadine. Annatina Saratz takes over the majority shareholding in Hotel Saratz. In the past financial year, the hotel achieved one of the best results in its recent history. Until now, Hotel
Kellerhals Carrard acts as lead Swiss legal and tax counsel to Ameliora Wealth Management in the acquisition of the Swiss offshore business of UBP Investment Advisors with American private clients. With this transaction, UBP, the
MLL Legal has acted as Swiss counsel to the financial investor Capiton on the acquisition of a majority stake in the Asyril Group, a market and technology leader in flexible parts feeding systems. Capiton has
Bär & Karrer has provided legal advice to the shareholder of Home Service who has sold its shares to Investis Holding. Home Service is a Swiss-based company active in the building services sector mainly
Baker McKenzie has advised the two owners of ARGO-HYTOS Group, Christian Kienzle and FSP CAPCELLENCE, on selling their 79.5% of the shares in the company to Voith Group, a German industrial technology group. Through this deal,
Schellenberg Wittmer advised Credaris on its purchase of credit intermediary Milenia. Both companies are Switzerland’s two leading credit intermediaries, and with this purchase agreement, Credaris will acquire 100% of the shares in Milenia. The Lausanne-based
+ND Capital has exited Dutch cell therapy company CellPoint by sale to the Belgian biotech company Galapagos which has acquired CellPoint for $131 million upfront and up to $105 million in milestone payments. As sole venture investor
Eurocine Vaccines and Redbiotec have signed a research and collaboration agreement for the development of vaccine candidates against herpes simplex virus type 2. Under the terms of the agreement, Eurocine will have exclusive international rights to
